INTRODUCTION
DNA methylation of CpG dinucleotides is one of the major epigenetic marks in mammals, and is known to have crucial roles in cellular processes including imprinting, gene expression regulation and control of differentiation. Mammalian enzymes catalyzing the conversion of cytosine to 5-methylcytosine (5-mC) by transferring a methyl group on the carbon 5 of cytosine belong to the DNA methyltransferase (DNMT) family including DNMT1, DNMT3A, DNMT3B and DNMT3L. Somatic heterozygous mutations in the DNMT3A gene have been reported in myeloid 1,2 and lymphoid malignancies, 3 and frequently target Arg882 (R882). The functional consequences of this mutant have been analyzed in murine embryonic stem cells, in which Dnmt3a R878H inhibits wild-type (WT) Dnmt3a and Dnmt3b. 4 In human, the DNMT3A R882H mutated protein presents as well a dominant-negative activity against DNMT3A WT by preventing the active homotetramer formation. 5 Dnmt3a-null mice present a hematopoietic stem /progenitor cells (HSPCs) expansion and differentiation bias toward B-cell compartment upon serial transplantations, those B lymphocytes retaining high expression of hematopoietic stem cell-associated genes. 6 Ten-Eleven-Translocation (TET) 2 catalyzes the conversion of 5-mC to 5-hydroxymethylcytosine (5-hmC) and may lead to active DNA demethylation. Loss-of-function mutations affecting TET2 gene have been described in human hematological malignancies affecting both myeloid and lymphoid lineages. [7] [8] [9] Studies in Tet2-inactivated mice revealed a cell-autonomous competitive advantage of hematopoietic progenitors followed by chronic myelomonocytic leukemia in a fraction of the animals. 10 This late malignant development in Tet2-inactivated context suggests that cooperative mutations are necessary for full-blown malignancy. Recently, such cooperations have been experimentally demonstrated in myeloid transformations in mice. [11] [12] [13] [14] [15] [16] [17] We previously reported a significant co-occurrence of TET2 and DNMT3A mutations in peripheral T-cell lymphoma patients; particularly frequent in angioimmunoblastic T-cell lymphoma (AITL). 3, 18, 19 TET2-mutated peripheral T-cell lymphoma shows a follicular helper T-cell (T fh ) signature and correlates with adverse outcome in patients. 20 Here, we explore the functional consequences of TET2 and DNMT3A mutations cooperation in hematopoiesis using a bone marrow transplantation (BMT) assay, in which mutant DNMT3A R882H is expressed in Tet2-inactivated (Tet2 −/− ) HSPC. Tet2 inactivation and DNMT3A R882H expression induced T-ALL or acute myeloid leukemia (AML) 6 months after transplantation. T-ALL is associated with hypermethylation and downregulation of tumor suppressor genes and hypomethylation and upregulation of Notch1 oncogene. The majority of serially transplanted mice developed an AITL-like disease closely resembling the human disease. Our data constitute the first cooperative murine model of T-cell malignancies involving Tet2 inactivation.
MATERIALS AND METHODS

Plasmid construction
Full-length human DNMT3A R882H , NOTCH1 L1601PΔP and TCL1A cDNA were subcloned into MSCV-GFP backbone. Retroviral preparations and transduction were performed as previously published. 21 Murine BMT BMT using 3-month-old C57BL/6 WT and Tet2 −/− donors was performed as described previously 8 leading to MSCV Tet2 +/+ , DNMT3A R882H Tet2 +/+ , MSCV Tet2 −/− (n = 20) and DNMT3A R882H Tet2 −/− (n = 18) mice. For serial transplantation, HSPCs were flow sorted from whole marrow 16 weeks after transplantation, using GFP + Lin − Kit + gating and engrafted with supplemented 2.5 × 10 5 total marrow in lethally irradiated recipients (n = 10). Animal experiments were approved by the Gustave Roussy animal care and use committees, according to ARRIVE guidelines.
Cell culture and western blotting
Culture of MO467, R152 and R338 cell lines, western blotting protocols and antibodies are described in Supplementary Methods.
Cell purification and cytometry
Total white blood cells from hematopoietic organs were stained in PBS supplemented with 2% FBS with fluorochrome-conjugated mouse antibodies against specific hematopoietic lineage markers. For the analysis of transplant-receiving mice, whole bone marrow was stained with fluorochrome-conjugated mouse antibodies to discriminate cells derived from competitors and donors (CD45.1 + and CD45.2 + , respectively), and GFP expression was used to precisely define donor-derived cells (GFP + CD45.2 + ). Fluorochrome-conjugated mouse antibodies were obtained from Becton Dickinson (Le Pont de Claix, France) (Streptavidin/PeCy5, CD117/PeCy7, CD45.1/PE, CD4/PE or PB, CD8/PeCy7 or APC, CD19/APC, B220/APCCy7, TCR β /PE, CD279/BV421, CD11b/PerCP-Cy5.5, Annexin V/APC, Ki67/PE) and eBiosciences (Paris, France) (CD117/APCCy7, Sca-1/APC, CD45.2/APC, Gr1/PE). Hoescht 33342 was obtained from Invitrogen (Villebon sur Yvette, France). APC BrdU Flow kit (Becton Dickinson) was used according to the manufacturer's instruction. Cell sorting was performed either on a MoFlow (Beckman Coulter, Villepinte, France) or on a Influx (Becton Dickinson) cell sorter; and analysis on a Canto II (Becton Dickinson). FACS data were analyzed by the FlowJo Software (v8.8.7, FlowJo, Ashland, OR, USA). Methylation and hydroxymethylation analyses by MeDIP and hMeDIP sequencing 5-mC and 5-hmC DNA immunoprecipitations of genomic DNA were performed as described. 22 In all, 200-500 bp genomic DNA fragments were obtained using the bioruptor (Diagenode, Liège, Belgium); and adaptor ligation was performed with the NEBNext DNA sample Prep Master Mix (New England Biolabs, Evry, France). One microgram of adaptor ligated DNA was heat denatured and incubated with an IgG control antibody or with polyclonal 5-hmC 22 or monoclonal 5-mC (Eurogentec, Angers, France) antibody. Dynabeads (Invitrogen) were added before immunoprecipitation; and elution of DNA was obtained with proteinase K digestion. PCR amplification of immunoprecipitated DNA was performed using index Illumina (Paris, France) multiplex primers and single-end sequenced on HiSeq-2000. Reads were aligned to mouse genome mm10 with BWA aln (v0.7.3a) and peak calling assessed with the R package MEDIPS (v1.10.0; Matthias Lienhard and Lukas Chavez, La Jolla, CA, USA). Differential analysis of (hydroxy)methylation was done with edgeR and annotation with HOMER (v4.7.2; Sven Heinz and Christopher Benner, La Jolla, CA, USA). Differentially (hydroxy)methylated regions with a P-value of o0.001 and an FC value of 41.5 were considered as significant. HOMER was also used for transcription factor binding motif discovery.
Reduced representation bisulfite sequencing
Reduced representation bisulfite sequencing (RRBS) libraries were prepared as described previously 23 with minor modifications. Genomic DNA (50-200ng) was digested for 5 h with MspI, end-repaired, A tailed and ligated with T4 DNA ligase (Fermentas, Villebon Sur Yvette, France) to methylated Illumina adaptors. In all, 150-400 bp fragments were gel-purified, bisulfite treated (EpiTect Bisulfite kit, Qiagen, Courtaboeuf, France); and RRBS libraries were amplified by 15 cycles of PCR with PfUTurbo Cx hotstar DNA polymerase (Agilent, Les Ulis, France) and indexed PE Illumina primers. The libraries were paired-end sequenced (2x75bp) on a HiSeq-2000 to an average of 30 million pairs of reads per sample. Raw reads were cleaned with Trim Galore (v0.2.1) and aligned to the mm10 genome with BSMAP (v2.74). We identified differentially methylated region (DMRs) with the eDMR algorithm from the methylKit R package with the following criteria: at least three CpGs, a difference in methylation greater than 20% and an adjusted P-value of o0.01. DMRs were annotated using the RefSeq mm10 transcript annotation.
RNAseq
RNA was extracted with the AllPrep kit (Qiagen), quantified as above and checked with Bioanalyzer (Agilent). SureSelect Automated Strand-Specific RNA Library Preparation Kit (Agilent) was used according to the manufacturer's instructions. Expression analysis was performed by counting the number of reads per gene using HTSeq-count; and differential expression was assessed using the R package DESeq. P-values o0.05 and − 2 oFC4 2 were used as thresholds for differentially expressed genes.
ChIPseq
ChIP analyses were performed according to the MagnaChIP kit (Millipore, St-Quentin-en-Yvelines, France). Briefly, 10 × 10 6 MO467 or R152 cells were prepared as previously published 24 with normal rabbit IgG (Millipore), H3K4me3 (Diagenode) and H3K27me3 (Millipore) antibodies. Adaptorligated libraries were prepared from 10ng of immunoprecipitated DNA using SPRIworks (Beckman Coulter). After indexed PCR amplification, the libraries were pooled and subjected to single-end sequencing. Reads were aligned to mouse genome mm10 with BWA aln (v0.7.5a) and peak calling assessed using MACS2 (v2.0.10.20131216) with a q-value cutoff of o0.05. Annotation has been done with HOMER (v4.7.2). 
Data access
Statistics
Data are depicted as mean ± s.e.m. as precised. P-values were calculated with the two-tailed unpaired Student's t-test. P-values for survival curves were calculated using a Log-rank (Mantel-Cox) test. All statistical analyses were performed with Prism software version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). The size of animal cohorts was based on our previous studies as well as the published literature. Neither randomization nor blinding was used, since all animal experiments were performed with homogeneous strain, age and similar variance.
RESULTS
Impairment of DNMT3A R882H Tet2 −/− HSPCs differentiation in vivo
We performed BMT assays using Tet2 wild-type (Tet2 +/+ ) or Tet2 −/− murine HSPC, transduced with DNMT3A R882H -expressing retroviruses. Monthly sampling of recipient mice revealed a mild growth advantage for DNMT3A R882H Tet2 −/− cells over nontransduced Tet2 −/− cells, as shown by the constant increase of GFP + cells in recipients. In contrast, empty vector or DNMT3A R882H expression alone did not confer growth advantage over untransduced cells in a Tet2 +/+ context (Figure 1a ). Engrafted cells showed efficient contribution to mature T, B and myeloid cells ( Figure 1b Figure S1A ).
However, an increased proportion of Lin − Kit + (LK) and Lin − Sca + Kit + (LSK) cells was observed when DNMT3A R882H is expressed (Figure 1d ), in keeping with previous reports showing increased contribution of Dnmt3a-inactivated cells to the stem/progenitor fraction. 6 Since Dnmt3a inactivation has been shown to impair HSPC differentiation upon serial transplantation, 6 we sorted GFP + LK progenitors of three DNMT3A R882H Tet2 −/− or Tet2 +/+ mice 16 weeks post transplantation and serially transplanted them into ten secondary mice. GFP + LK progenitors from three secondary mice were engrafted in 10 tertiary recipients. DNMT3A R882H Tet2 −/− cells showed efficient participation to mature blood cells in both secondary and tertiary experiments, indicating their self-renewal capacity, whereas DNMT3A R882H Tet2 +/+ progenitors were progressively diluted (Figure 1e ). Detailed analyses showed that the contribution of the donor-derived cells to mature lineages differs between Tet2 contexts in both secondary and tertiary transplantations ( Figure 1f ). Expression of DNMT3A R882H in Tet2 +/+ context induced an increase in the B-cell fraction, in keeping with the reported B-cell bias of Dnmt3a-inactivated HSPCs. 6 Expression of DNMT3A R882H in Tet2 − / − progenitors led to an expansion of the T-cell compartment in blood in both secondary and tertiary transplantations. However, DNMT3A R882H Tet2 −/− marrow examination did not show significant differences in lineage contribution in secondary transplant (Figure 1g , left) while 3 ary transplants showed an accumulation of mature myeloid cells in marrow as compared with DNMT3A R882H Tet2 +/+ mice (Figure 1g , right).
As expected for Tet2 −/− cells, the proportion of DNMT3A R882H Tet2 −/− HSPC in the bone marrow was significantly higher, compared with DNMT3A R882H Tet2 +/+ HSPC in secondary and tertiary transplanted recipients ( Figure 1h ). No difference in thymic populations repartition between DNMT3A R882H Tet2 − / − and DNMT3A R882H Tet2 +/+ secondary recipients was observed (Supplementary Figure S1B ). Overall, these results indicate cooperation of the DNMT3A R882H mutant with Tet2 inactivation leading to differential accumulation of DNMT3A R882H Tet2 − / − cells in hematopoietic organs, with myeloid cells primarily in the marrow and T cells in the blood.
AITL-like development in DNMT3A R882H Tet2 −/− serially transplanted engrafted mice During the course of the monitoring (10-16 months after transplantation), we killed four (out of six secondary) and five (out of six tertiary) DNMT3A R882H Tet2 −/− mice, based on peripheral cytopenia and splenomegaly (Table 1) . Analyses identified enlarged thymus, along with an expansion of the CD4 + T-cell population in the thymus (Figure 2a , left) and in all hematopoietic organs investigated (data not shown). Since human AITL is associated with high PD1 expression levels, we investigated its expression in DNMT3A R882H Tet2 −/− T-cell populations. Cell surface expression of PD1 was observed on GFP + CD4 + cells in every tissue, including lymph nodes (Figure 2a , right). Histopathological analysis of DNMT3A R882H Tet2 −/− symptomatic mice showed an infiltration of both the splenic white pulp and the liver by pleomorphic predominantly small to medium lymphoid cells accompanied by eosinophils, plasma cells and a few scattered larger cells resulting in alteration of the normal liver architecture with some focused perivascular infiltrations (Figure 2b) . The proliferation was essentially composed of CD3 + and PD1 + atypical T cells, whereas CD79a staining highlighted recruitment of a few large B lymphocytes in addition to the plasmocytes around T-cell infiltrates, therefore mimicking the pathological and phenotypic features of human AITL. The AITL phenotype was further underscored by the high expression of Bcl6, Pdcd1, Cxcr5 and Icos genes, 25, 26 in GFP + CD4 + DNMT3A R882H Tet2 −/− cells as compared with normal Tet2 +/+ CD4 + thymocytes (Figure 2c ). Together, these data showed that 75% (9/12) of mice serially engrafted with DNMT3A R882H Tet2 −/− progenitors developed an AITL-like disease.
Mice transplanted with DNMT3A R882H Tet2 −/− HSPC die prematurely and develop acute leukemias We monitored disease development in primary recipients for 1 year. Tet2 +/+ , Tet2 −/− and DNMT3A R882H Tet2 +/+ transplanted mice remained healthy throughout the period, whereas among the 18 DNMT3A R882H Tet2 −/− primary engrafted mice, 1 showed symptoms of AITL-like disease, 4 developed AML-like or T-ALLlike diseases, and the mice were killed around 6 months post engraftment ( Figure 3a and Table 1 ).
The two AML-like DNMT3A R882H Tet2 −/− mice exhibited hepatosplenomegaly and additional adenopathy (Table 1 ) consistent with 80% of Mac1 + Gr1 + Kit + blastic myeloid population in the marrow (Figure 3b , left). Secondary transplantation experiments performed with one of the AML sample also confirmed the malignant nature of the tumor (data not shown). Bone marrow from T-ALL-like DNMT3A R882H Tet2 −/− recipients exhibited more (Figure 3b, right) , which induced a similar T-ALL to transplanted recipients (Supplementary Figure S2A) . Histopathological analysis showed alteration in the normal liver architecture with significant diffuse T-cell infiltration accompanied with focused perivascular infiltrations (Supplementary Figure S2B) . These findings show that DNMT3A R882H Tet2 −/− progenitors are predisposed to both myeloid and lymphoid acute transformation in vivo.
Concomitant ablation of Tet2 and overexpression of DNMT3A R882H
induce both global and local changes of 5-hmC and 5-mC epigenomic patterns As the amount of material available from AITL-like mice was not sufficient, we then used DNMT3A R882H Tet2 −/− T-ALL models to investigate the mechanism underlying T-cell transformation using expression and methylation analyses. First, we performed transcriptome profiling of DNMT3A R882H Tet2 −/− T-ALL samples as well as T-ALL generated by BMT using known T-cell oncogenes: TCL1A 27 and NOTCH1 L1601PΔP . 28 We used DP thymocytes from Tet2 −/− and Tet2 +/+ mice as a reference ( Supplementary Table S1 ). Principal component analysis based on global expression profiles Supplementary Table S2 .
Tet2 − / − DNMT3A R882H leads to lymphoid malignancies L Scourzic et al ( Supplementary Table S2 ) presented a marked overlap with known Notch pathway signatures (Figure 3c, right) , consistent with their clustering close to NOTCH1 L1601PΔP T-ALL samples in the principal component analysis. Next, we compared DNA (hydroxy)methylation profiles between DNMT3A R882H Tet2 −/− T-ALLs, normal Tet2 −/− thymocytes and other murine T-ALL samples ( Supplementary Table S1 ). Analyses of the combination of these samples allowed us to associate DNA (hydroxy)methylation changes to Tet2 inactivation, DNMT3A R882H mutant or the cooperation of Tet2-inactivation and DNMT3A R882H mutant. First, we analyzed hydroxymethylated and methylated DNA immunoprecipitation (hMeDIP and MeDIP, respectively) sequencing data ( Supplementary Tables S3 and S4 ).
Global hydroxymethylation is modified upon Tet2 inactivation, with almost all differentially hydroxymethylated regions (DhMRs) being hypo-hydroxymethylated (Figure 4a , top) and located in intergenic regions (Supplementary Figure S3A) as expected from the proposed function of Tet2 in regulating enhancer activity. 15, 29 Tet2 inactivation was also associated with both hyper (n = 1115) and hypo (n = 90) DMRs (Figure 4a, bottom) . DNMT3A R882H was not associated with hypo-DhMR but with some hyper-DhMRs, suggesting deregulation of the control of DNA hydroxymethylation. Both hyper and hypo-DMRs were in greater numbers in DNMT3A R882H than for Tet2 inactivation (2929 and 347, respectively), and frequently located in promoter regions for hypermethylation and in gene bodies for hypomethylation. The cooperation between those two previous conditions led to further deregulation of hydroxymethylation, some regions presenting less 5-hmC and some others more. The combination of both Tet2inactivation and DNMT3A R882H mutant presented almost the same number of DMR as compared with DNMT3A R882H mutant alone, and did not markedly affect the repartition within the different genome annotations.
We then specifically analyzed the methylation at CpG island regions through the mouse genome, by representing the coverage of reads obtained from hMeDIP and MeDIP (Figure 4b ). Tet2 inactivation was not associated with marked changes in 5-hmC or 5-mC contents, whereas DNMT3A R882H mutant expression was associated with higher 5-hmC levels and a strong increase in 5-mC. To obtain a more precise analysis of CpG methylation in DNMT3A R882H Tet2 −/− tumors, we performed RRBS on the same samples ( Supplementary Table S1 ). CpG methylation was increased in DNMT3A R882H Tet2 −/− samples with respect to other T-ALLs and Tet2 − / − samples (Supplementary Figure S3B) and DMRs could be identified between samples ( Supplementary Table S5 ).
Specific transcriptional changes in tumoral DNMT3A R882H Tet2 −/− cells Mean expression in Tet2 −/− context of DMR-associated gene showed statistical differences only when DMRs were located within gene bodies, hyper-DMR being associated with higher expression and hypo-DMR with low expression (Figure 5a ). With DNMT3A R882H mutant and Tet2 inactivation, hyper-DMRs were associated with lower gene expression, whereas hypo-DMRs were associated with higher expression.
We identified the genes that were statistically both hypermethylated and underexpressed in DNMT3A R882H Tet2 −/− cells (Figure 5b, top) . 215 methylated CpG regions lie within 110 genes ( Supplementary Table S6 ). The sequences of the methylated CpG regions significantly showed DNA binding sequences of T-cell transcription factors, Thpok (Zbtb7b), Tcf1 and Tcf7 (Supplementary Figure S4A ). Thpok is a key regulator of CD4 lymphocytes differentiation and upregulated in DNMT3A R882H Tet2 −/− cells as compared with Tet2 − / − cells (data not shown). Tcf1 is a known tumor suppressor in T-cell transformation and a negative regulator of the Notch pathway. [30] [31] [32] Methylation of its target sites may mimic inactivation of the gene itself, as suggested here by the statistically significant downregulation of the β-catenin pathway (Figure 3c ). Other tumor suppressor genes, known to be inactivated during hematopoietic transformation such as Inpp4b 33, 34 and Tle4 (ref. 35) were among the 110 genes that both were hypermethylated and downregulated. An additional example is Kdm5b, which encodes a H3K4 demethylase (Figure 5b,  bottom) .
Nine genes were statistically both hypomethylated and overexpressed ( Figure 5c top and Supplementary Table S7 Figure S4B , bottom), the hypomethylated regions are also located in the 3' part of the gene (Supplementary Figure S4C) . To assess histone methylation marks associated with transcription activation or repression on Notch1 and Dtx1 loci, we performed ChIPseq on DNMT3A R882H Tet2 −/− (MO467) or NOTCH1 L1601PΔP Tet2 +/+ (R152) murine T-ALL established cell lines ( Supplementary Table S1 ). Hypermethylated regions were associated with less H3K4me3, whereas hypomethylated regions were associated with H3K4me3 enrichment (Figure 5c bottom and Supplementary Figure S4D ). Altogether, these results highlight a synergistic effect of Tet2 −/− inactivation and DNMT3A R882H overexpression on DNA methylation and gene expression, resulting in both downregulation of tumor suppressor genes and upregulation of oncogenes, including Notch pathway genes.
Notch dependency of tumor DNMT3A R882H Tet2 −/− cells To functionally assess the role of the Notch pathway in this transformation process, we studied Notch dependency of MO467 (DNMT3A R882H Tet2 −/− ) and R152 (NOTCH1 L1601PΔP Tet2 +/+ ) established T-ALL cell lines. Activation of the Notch pathway in MO467 cells was confirmed by the presence of cleaved Notch1 proteins (Figure 6a, left) . Treatment of the cell lines with increasing amount of a γ-secretase inhibitor (GSI) led to decreased expression of the cleaved form of Notch1 (Figure 6a , right) and decreased expression of known Notch1 target genes: such as Hes1 and Nrarp (Figure 6b ). GSI treatment led to reduced viability/ proliferation of DNMT3A R882H Tet2 −/− and NOTCH1 L1601PΔP Tet2 +/+ Table S1 ).
Tet2 − / − DNMT3A R882H leads to lymphoid malignancies L Scourzic et al cells but not of Ba/F3 cells (Figure 6c ) and was associated with an increased proportion of cells in G0/G1 and decrease of cells in S-phase in both DNMT3A R882H Tet2 −/− ( Supplementary Figure S5A and B) and NOTCH1 L1601PΔP Tet2 +/+ (data not shown) cell lines. We confirmed these results by treating R158 (NOTCH1 L1601PΔP Tet2 −/− ) and R467 (DNMT3A R882H Tet2 −/− ) primary cells cultured on MS5 and MS5-DL1 feeders, with another GSI (DAPT). DNMT3A R882H Tet2 −/− T-ALL cells proliferate in a Notch-dependent manner similarly to NOTCH1 L1601PΔP Tet2 − / − T-ALL cells, although they do not respond to classical Notch activation by DL1 ligand (Supplementary Figure S5C ). Furthermore, an increased proportion of both apoptotic and G0/G1 DNMT3A R882H Tet2 −/− T-ALL cells is observed ( Supplementary Figure S5D and E).
DISCUSSION
Here, we report that concomitant DNMT3A R882H expression and loss of Tet2 in mouse HSPC lead to both myeloid and lymphoid hematological malignancies. The AML-like disease developed by 10% of DNMT3A R882H Tet2 − / − mice is consistent with the recurrence of these mutations in human AML. The T-lymphoid diseases are more frequent, in keeping with the tight association between these mutations in human AITL. As the abnormal expansion of myeloid and T cells is observed in different organs, marrow and blood respectively, the microenvironment may have an important role in determining the amplified linages. 36 Our model represents the first cooperative murine model involving Tet2 inactivation in T-cell malignancies. In many aspects, these results are in accordance with Dnmt3a-null mice, which also develop both lymphoid and myeloid malignancies. 37, 38 We however did not observe B-cell malignancies, in keeping with the human situation: B-lymphoid malignancies essentially lack DNMT3A mutations in human.
The combination of Tet2 loss and DNMT3A R882H expression resulted in high hydroxymethylation and methylation disorder. DNMT3A R882H -associated hypermethylation correlated with low expression of tumor suppressor loci and hypomethylation associated with high expression of oncogene. In our model, among the widespread DNA methylation aberrations, only few genes may have functional impact. This is exemplified by hypomethylation and overexpression of the Notch1 and Dtx1 genes, which results in the activation of the Notch pathway, a major oncogenic pathway in T-cell malignancies. Other abnormalities may sustain T-cell transformation, such as low expression of Tcf1, leading to the downregulation of the Wnt/β catenin pathway, as reported in a fraction of peripheral T-cell lymphoma, 39 together with methylation of the promoters of target genes. Overexpression of Zbtb7b may be involved in the generation of hyper-DMRs and cellular transformation. 40 Finally, the high frequency of DNMT3A mutations in adult T-ALL 41,42 may be associated with NOTCH1 hypomethylation causing high NOTCH1 expression during T-cell differentiation and subsequent occurrence of NOTCH1 activation mutation to induce T-ALL. With age, our mouse model consistently develops an AITL-like disease, a lymphoma occurring in the elderly in human and for which only few mouse models exist. 43, 44 Given that AITL cells could not be engrafted aside from subsequent progenitors transplantation along with a decrease in the GFP + proportion, their isolation in sufficient number for functional analyses was precluded. The AITL phase is preceded by an expansion of the CD4 + T-cell compartment, and associated with high Notch1 and Dtx1 expression (data not shown). The link between early expansion of the CD4 + population and subsequent development of AITL-like disorder is at the moment speculative, but may rely on high expression Thpok and of Notch1 during thymocytes differentiation. Recently, immunohistochemical 45 The relative low number of transformations observed in primary recipients likely reflects the insufficiency of TET2 and DNMT3A mutations to drive full transformation. The observed bias toward T-cell abnormalities might be due to impaired methylation, which has been suggested to protect from lymphoid differentiation. 46 Serial transplantations might facilitate epigenetic drift, leading to Notch1 overexpression and CD4 + T-cell accumulation.
Together, our data support the idea that Notch pathway activation represents an important survival signal for abnormal T fh cells. Interaction with B lymphocyte and myeloid cells might substitute for Notch survival signals required by these abnormal T fh cells 47 and/or for T-cell survival. 48 
